RecruitingPhase 1NCT04429542
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Studying Squamous cell carcinoma of head and neck
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bicara Therapeutics
- Intervention
- BCA101(drug)
- Enrollment
- 292 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (20)
- Moores Cancer Center UC San Diego Health, La Jolla, California, United States
- Keck School of Medicine of USC, Los Angeles, California, United States
- UCLA, Los Angeles, California, United States
- University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
- H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa, Florida, United States
- Dana Farber/Partners Cancer Care Inc, Boston, Massachusetts, United States
- Memorial Sloan Kettering, New York, New York, United States
- Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York, United States
- Levine Cancer Institute, Charlotte, North Carolina, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
- Rhode Island Hospital, Providence, Rhode Island, United States
- Medical University of South Carolina, Hollings Cancer Center, Charleston, South Carolina, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- +5 more locations on ClinicalTrials.gov
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04429542 on ClinicalTrials.govOther trials for Squamous cell carcinoma of head and neck
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07333274Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE3NCT07026474Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCUniversität des Saarlandes
- RECRUITINGPHASE1NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNormunity AccelCo, Inc.
- RECRUITINGNANCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled TrialTobias Todsen
- RECRUITINGNANCT07180901Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck CancerCentre hospitalier de l'Université de Montréal (CHUM)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415Local Injection Methylene Blue Combined With Radiation in HNSCC PatientsChina Medical University Hospital
- RECRUITINGPHASE2NCT07088211Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- RECRUITINGPHASE2NCT07040956A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.West China Hospital
See all trials for Squamous cell carcinoma of head and neck →